Bids Are Invited For Price Registration, For A Period Of 1 Year, Which May Be Extended For The Same Period, As Long As The Advantageous Price Is Proven, For Future And Eventual Acquisition Of Medicines Court Demand 12

(L1) 6501.83479-Avelumab, 20 Mg/Ml, Solution For Dilution For Infusion, Ampoule Vial, 10 Ml, Route Of Administration: Intravenous, Units. Size: Unit, (L2) 6501.40536-Carfilzomib, 60Mg, Lyophilized Powder For Injectable Solution, (L3) 6501.49767-Daratumumab, 100Mg, Injectable Solution, 5Ml, (L4) 6501.48228-Daratumumab, 400Mg, Vial 20Ml, (L5) 6501.105741-Galcanezumab, 100 Mg/Ml, Prefilled Syringe, 1 Ml, (L6) 6501.1318-Ganciclovir, 1 Mg/Ml (500 Mg) - In 0.9% Sodium Chloride Solution, Pouch/Vial (Closed System), 500 Ml, (L7) 6501.94252-Subcutaneous Purified Immunoglobulin G, 5 G, Route Of Administration: Subcutaneous, (L8) 6501.93967-Inclisiran, 284Mg/1.5Ml, (L9) 6501.112812-Lebrikizumab, 125 Mg/Ml, 2 Ml, (L10) 6501.23074-Liraglutide, 6 Mg/Ml, Carpule, 3 Ml, Applicator Pen, Application System With Dispensing Doses From 0.6 To 1.8 Mg, (L11) 6501.60958-Liraglutide, 6 To 3.0 Mg, (L12) 6501.112597-Nirsevimab, 100Mg, 1Ml (100Mg/Ml), Route Of Administration: Intramuscular, (L13) 6501.114185-Nivolumab + Relatlimab, 12 Mg/Ml + 4 Mg/Ml, 20Ml Bottle, (L14) 6501.48257-Rituximab, 1,400Mg, 11.7Ml, (L15) 6501.113853-Tirzepatide, 10Mg, 0.5Ml, 20Mg/Ml